Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 748,700 shares, a drop of 33.7% from the February 13th total of 1,130,000 shares. Based on an average daily trading volume, of 56,200 shares, the short-interest ratio is currently 13.3 days. Approximately 3.5% of the company’s stock are short sold.
Analyst Ratings Changes
ACRV has been the topic of several research analyst reports. KeyCorp assumed coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. Cantor Fitzgerald started coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.67.
Get Our Latest Stock Report on ACRV
Hedge Funds Weigh In On Acrivon Therapeutics
Acrivon Therapeutics Stock Performance
Shares of ACRV stock opened at $5.44 on Monday. The stock’s 50 day simple moving average is $5.62 and its 200 day simple moving average is $6.80. Acrivon Therapeutics has a twelve month low of $4.69 and a twelve month high of $11.90. The company has a market capitalization of $169.38 million, a price-to-earnings ratio of -2.01 and a beta of 0.85.
Acrivon Therapeutics Company Profile
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Stories
- Five stocks we like better than Acrivon Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How to Build the Ultimate Everything ETF Portfolio
- The Significance of Brokerage Rankings in Stock Selection
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.